ICI Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, England.
Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):67S-69S.
Xamoterol has been shown in large, double-blind studies to produce benefit in patients with heart failure. Ischaemic heart disease is the commonest cause of heart failure in the Western World and many patients with heart failure also have angina pectoris (Califf et al., 1982). In view of the known anti-ischaemic effects of xamoterol, we analysed the results of a subgroup of 269 patients with heart failure but without chest pain as a limiting factor on exercise to compare the efficacy of xamoterol in such patients with that of the total group. There were no differences in exercise heart rate, exercise tolerance and symptoms in patients without chest pain compared with the total group. Xamoterol is probably, therefore, acting through myocardial mechanisms other than an anti-ischaemic effect.
在大规模双盲研究中已表明，Xamoterol对心力衰竭患者有益。缺血性心脏病是西方世界心力衰竭最常见的病因，许多心力衰竭患者也患有心绞痛（Califf等人，1982年）。鉴于Xamoterol已知的抗缺血作用，我们分析了269例心力衰竭患者亚组的结果，这些患者无胸痛作为运动的限制因素，以比较Xamoterol在此类患者与整个组中的疗效。与整个组相比，无胸痛患者的运动心率、运动耐量和症状无差异。因此，Xamoterol可能是通过除抗缺血作用之外的心肌机制起作用。
